StockData
Assembly Biosciences, Inc. logo

Assembly Biosciences, Inc. (ASMB) stock

ASMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/309% below fair value
$22.50+1.21 (+5.68%)

Close on Nov 17, 2026Market cap $458.11MP/E –Yield –

Assembly Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

Assembly Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $63.65M, up 8.3% year over year. For fiscal 2025 it was $64.81M, up 15.9% from the year before. Over ten years it grew 13.4% a year on average. The highest annual figure on record is $106.82M in fiscal 2020.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$64.81M+15.9%
FY2024Dec 31, 2024$55.93M+14.4%
FY2023Dec 31, 2023$48.90M-30.1%
FY2022Dec 31, 2022$69.98M+2.1%
FY2021Dec 31, 2021$68.52M-35.9%
FY2020Dec 31, 2020$106.82M+24.6%
FY2019Dec 31, 2019$85.76M+17.9%
FY2018Dec 31, 2018$72.74M+64.5%
FY2017Dec 31, 2017$44.23M+33.6%
FY2016Dec 31, 2016$33.09M+80.3%
FY2015Dec 31, 2015$18.36M+71.3%
FY2014Dec 31, 2014$10.72M-28.7%
FY2013Dec 31, 2013$15.03M-23.0%
FY2012Dec 31, 2012$19.51M-22.8%
FY2011Dec 31, 2011$25.28M+1265.9%
FY2010Dec 31, 2010$1.85M-37.1%
FY2009Dec 31, 2009$2.94M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$14.92M-7.5%
Q1 FY2026Mar 31, 2026$14.90M+0.3%
Q4 FY2025Dec 31, 2025$17.25M+20.8%
Q3 FY2025Sep 30, 2025$16.59M+22.7%
Q2 FY2025Jun 30, 2025$16.13M-0.8%
Q1 FY2025Mar 31, 2025$14.85M+25.0%
Q4 FY2024Dec 31, 2024$14.28M+29.7%
Q3 FY2024Sep 30, 2024$13.52M+24.9%
Q2 FY2024Jun 30, 2024$16.26M+29.8%
Q1 FY2024Mar 31, 2024$11.88M-18.3%
Q4 FY2023Dec 31, 2023$11.01M-34.7%
Q3 FY2023Sep 30, 2023$10.82M-40.3%
Q2 FY2023Jun 30, 2023$12.52M-29.6%
Q1 FY2023Mar 31, 2023$14.55M-15.4%
Q4 FY2022Dec 31, 2022$16.85M+14.3%
Q3 FY2022Sep 30, 2022$18.13M-1.9%
Q2 FY2022Jun 30, 2022$17.79M+6.2%
Q1 FY2022Mar 31, 2022$17.21M-7.3%
Q4 FY2021Dec 31, 2021$14.75M-56.0%
Q3 FY2021Sep 30, 2021$18.47M-31.4%
Q2 FY2021Jun 30, 2021$16.75M-28.2%
Q1 FY2021Mar 31, 2021$18.55M-19.5%
Q4 FY2020Dec 31, 2020$33.51M+48.2%
Q3 FY2020Sep 30, 2020$26.94M+23.9%
Q2 FY2020Jun 30, 2020$23.33M+24.7%
Q1 FY2020Mar 31, 2020$23.05M+1.5%
Q4 FY2019Dec 31, 2019$22.62M+6.4%
Q3 FY2019Sep 30, 2019$21.74M+13.7%
Q2 FY2019Jun 30, 2019$18.70M+4.8%
Q1 FY2019Mar 31, 2019$22.70M+56.1%
Q4 FY2018Dec 31, 2018$21.25M+100.5%
Q3 FY2018Sep 30, 2018$19.11M+74.8%
Q2 FY2018Jun 30, 2018$17.84M+47.1%
Q1 FY2018Mar 31, 2018$14.54M+37.5%
Q4 FY2017Dec 31, 2017$10.60M+22.9%
Q3 FY2017Sep 30, 2017$10.93M+23.7%
Q2 FY2017Jun 30, 2017$12.13M–
Q1 FY2017Mar 31, 2017$10.57M–
Q4 FY2016Dec 31, 2016$8.62M–
Q3 FY2016Sep 30, 2016$8.83M–

More Assembly Biosciences figures

See a number that looks wrong?